Kempharm Stock Buy Hold or Sell Recommendation

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Kempharm is 'Buy'. Macroaxis provides Kempharm buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Kempharm positions. The advice algorithm takes into account all of Kempharm's available fundamental, technical, and predictive indicators you will find on this site.

Search Advice 

 
Refresh
The advice is provided from Kempharm's buy-and-hold perspective. Please see Kempharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Kempharm and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Kempharm.

Execute Kempharm Buy or Sell Advice

The Kempharm recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kempharm. Macroaxis does not own or have any residual interests in Kempharm or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kempharm's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell KempharmBuy Kempharm
Buy

Volatility

Somewhat reliableDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds of Distress

Very LowDetails

Economic Sensitivity

Follows the market closelyDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Kempharm has a Risk Adjusted Performance of 0.0721, Jensen Alpha of 0.2689, Total Risk Alpha of 0.132, Sortino Ratio of 0.0693 and Treynor Ratio of 0.3756
Our investment recommendation tool can cross-verify current analyst consensus on Kempharm and to analyze the entity potential to grow in the current economic cycle. To make sure Kempharm is not overpriced, please verify all Kempharm fundamentals, including its price to book, current ratio, working capital, as well as the relationship between the net income and number of employees . Given that Kempharm has a number of shares shorted of 3.55 M, we recommend you to check Kempharm market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your last-minute risk tolerance and investing horizon.

Kempharm Trading Alerts and Improvement Suggestions

Kempharm has very high historical volatility over the last 90 days
Kempharm was previously known as Kempharm and was traded on NASDAQ Exchange under the symbol KMPHD.
The company reported the previous year's revenue of 23.32 M. Net Loss for the year was (54.75 M) with profit before overhead, payroll, taxes, and interest of 11.98 M.
Kempharm currently holds about 75.92 M in cash with (2.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.66.
Kempharm has a frail financial position based on the latest SEC disclosures
Roughly 15.0% of the company outstanding shares are owned by corporate insiders
Latest headline from www.cmlviz.com: KMPH KemPharm Announces U.S. Launch Of Innovative ADHD Treatment Azstarys By Corium - CML News

Kempharm current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kempharm analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kempharm analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price19.00
Target Median Price19.00
Target High Price28.00
Recommendation Mean2.50
Number Of Analyst Opinions2
Target Low Price10.00
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Kempharm Returns Distribution Density

The distribution of Kempharm's historical returns is an attempt to chart the future uncertainty of Kempharm's future price movements. The chart of the probability distribution of Kempharm stock daily returns describes the distribution of returns around its average expected value. We use Kempharm price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kempharm returns is essential to provide solid investment advice for Kempharm stock.
Mean Return0.31Value At Risk-6.42
Potential Upside6.15Standard Deviation3.50
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kempharm historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Kempharm Cash Flow Accounts

201620172018201920202021 (projected)
Capital Expenditure(643 K)(181 K)(21 K)(26 K)(33 K)(35.61 K)
Depreciation Amortization and Accretion175 K336 K324 K304 K273 K262.3 K
Net Cash Flow or Change in Cash and Cash Equivalents(14.46 M)(5.89 M)7.15 M(15.56 M)767 K827.55 K
Issuance Repayment of Debt Securities62.17 M(157 K)(193 K)4.94 M2.82 M2.9 M
Net Cash Flow from Financing61.16 M(203 K)28.02 M4.94 M2.74 M2.81 M
Net Cash Flow from Investing(45.85 M)27.41 M33.33 M3.23 M(33 K)(35.61 K)
Net Cash Flow Investment Acquisitions and Disposals(45.2 M)27.59 M33.35 M3.26 M3.75 M4.04 M
Net Cash Flow from Operations(29.77 M)(33.1 M)(54.2 M)(23.74 M)(1.94 M)(2.09 M)
Share Based Compensation6.6 M4.56 M6.5 M4.41 M2.49 M3.28 M

Kempharm Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kempharm or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kempharm stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kempharm stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
0.27
β
Beta against DOW0.79
σ
Overall volatility
3.61
Ir
Information ratio 0.07

Kempharm Volatility Alert

Kempharm shows above-average downside volatility for the selected time horizon. We advise investors to inspect Kempharm further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Kempharm future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Kempharm's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Kempharm's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Kempharm Fundamentals Vs Peers

Comparing Kempharm's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kempharm's direct or indirect competition across all of the common fundamentals between Kempharm and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kempharm or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kempharm's fundamental indicators could also be used in its relative valuation, which is a method of valuing Kempharm by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Kempharm to competition
FundamentalsKempharmPeer Average
Return On Equity(222.16) %(0.31) %
Return On Asset6.45 %(0.14) %
Profit Margin(74.21) %(1.27) %
Operating Margin21.98 %(5.51) %
Current Valuation328.5 M16.62 B
Shares Outstanding28.51 M571.82 M
Shares Owned by Insiders14.73 %10.09 %
Shares Owned by Institutions16.03 %39.21 %
Number of Shares Shorted3.55 M4.71 M
Price to Earning(1.21) X28.72 X
Price to Book3.64 X9.51 X
Price to Sales13.16 X11.42 X
Revenue23.32 M9.43 B
Gross Profit11.98 M27.38 B
EBITDA5.39 M3.9 B
Net Income(54.75 M)570.98 M
Cash and Equivalents75.92 M2.7 B
Cash per Share2.66 X5.01 X
Total Debt2.75 M5.32 B
Debt to Equity0.032 %48.70 %
Current Ratio20.70 X2.16 X
Book Value Per Share2.96 X1.93 K
Cash Flow from Operations(2.5 M)971.22 M
Short Ratio6.11 X4.00 X
Earnings Per Share(6.83) X3.12 X
Number of Employees2218.84 K
Beta3.36-0.15
Market Capitalization306.74 M19.03 B
Total Asset54.59 M29.47 B
Retained Earnings(252.18 M)9.33 B
Working Capital45.74 M1.48 B
Current Asset54.08 M9.34 B
Current Liabilities8.34 M7.9 B
   Purchase by Clifton R Laduane of tradable shares of Kempharm [view details]

About Kempharm Buy or Sell Advice

When is the right time to buy or sell Kempharm? Buying financial instruments such as Kempharm Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Kempharm investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2018 2019 2020 2021 (projected)
Current Assets23.72 M6.97 M8.38 M8.6 M
Total Assets26.75 M10.51 M11.21 M11.5 M

Use Investing Ideas to Build Portfolios

In addition to having Kempharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recreation Thematic Idea Now

Recreation
Recreation Theme
Companies involved in production and services of recreational goods, foods, and accessories. Recreation theme has 17 constituents.
View All  Next Launch Recreation
Please see Kempharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.